Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE)
Background: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2 August 2016
|
| In: |
Oncology research and treatment
Year: 2016, Volume: 39, Issue: 9, Pages: 539-547 |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000448085 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1159/000448085 Verlag, Volltext: http://www.karger.com/Article/FullText/448085 
|
| Author Notes: | Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, Jörg Mezger, Mark A. Socinski, Henrik Depenbrock, Victoria Soldatenkova, Jacqueline Brown, Thomas Krause, Nick Thatcher |
| Summary: | Background: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N |
|---|---|
| Item Description: | Gesehen am 13.02.2018 |
| Physical Description: | Online Resource |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000448085 |